» Articles » PMID: 35564982

Persistence of Adverse Drug Reaction-Related Hospitalization Risk Following Discharge

Overview
Publisher MDPI
Date 2022 May 14
PMID 35564982
Authors
Affiliations
Soon will be listed here.
Abstract

This retrospective cohort study analyzed the administrative hospital records of 91,500 patients with the aim of assessing adverse drug reaction (ADR)-related hospital admission risk after discharge from ADR and non-ADR-related admission. Patients aged ≥18 years with an acute admission to public hospitals in Tasmania, Australia between 2011 and 2015 were followed until May 2017. The index admissions (n = 91,550) were stratified based on whether they were ADR-related (n = 2843, 3.1%) or non-ADR-related (n = 88,707, 96.9%). Survival analysis assessed the post-index ADR-related admission risk using (1) the full dataset, and (2) a matched subset of patients using a propensity score analysis. Logistic regression was used to identify the risk factors for ADR-related admissions within 90 days of post-index discharge. The patients with an ADR-related index admission were almost five times more likely to experience another ADR-related admission within 90 days (p < 0.001). An increased risk persisted for at least 5 years (p < 0.001), which was substantially longer than previously reported. From the matched subset of patients, the risk of ADR-related admission within 90 and 365 days more than doubled in the patients with an ADR-related index admission (p < 0.0001). These admissions were often attributed to the same drug class as the patients’ index ADR-related admission. Cancer was a major risk factor for ADR-related re-hospitalization within 90 days; other factors included heart failure and increasing age.

Citing Articles

Characteristics of CYP3A4-related potential drug-drug interactions in outpatients receiving prescriptions from multiple clinical departments.

Matsuoka R, Akagi S, Konishi T, Kondo M, Matsubara H, Yamamoto S J Pharm Health Care Sci. 2024; 10(1):48.

PMID: 39103904 PMC: 11299250. DOI: 10.1186/s40780-024-00368-4.

References
1.
Wastesson J, Morin L, Tan E, Johnell K . An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf. 2018; 17(12):1185-1196. DOI: 10.1080/14740338.2018.1546841. View

2.
Davies E, Green C, Mottram D, Rowe P, Pirmohamed M . Emergency re-admissions to hospital due to adverse drug reactions within 1 year of the index admission. Br J Clin Pharmacol. 2010; 70(5):749-55. PMC: 2997315. DOI: 10.1111/j.1365-2125.2010.03751.x. View

3.
Parameswaran Nair N, Chalmers L, Bereznicki B, Curtain C, Peterson G, Connolly M . Adverse Drug Reaction-Related Hospitalizations in Elderly Australians: A Prospective Cross-Sectional Study in Two Tasmanian Hospitals. Drug Saf. 2017; 40(7):597-606. DOI: 10.1007/s40264-017-0528-z. View

4.
Parameswaran Nair N, Chalmers L, Peterson G, Bereznicki B, Curtain C, Bereznicki L . Prospective identification versus administrative coding of adverse drug reaction-related hospitalizations in the elderly: A comparative analysis. Pharmacoepidemiol Drug Saf. 2018; 27(11):1281-1285. DOI: 10.1002/pds.4667. View

5.
Hakkarainen K, Hedna K, Petzold M, Hagg S . Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions--a meta-analysis. PLoS One. 2012; 7(3):e33236. PMC: 3305295. DOI: 10.1371/journal.pone.0033236. View